Fig 10. Example scenario for distribution of available HRHA across HIV stages in the model, reflecting an 80/20 distribution of patients on ART/TasP, i.e., 80% of treated patients on ART (CD4 cell count ≤350 μl) and 20% on TasP (CD4 cell count >350 μl).